<span item_type="fundamental" item_id="c5b202401e346bfe5d4eb7a736a9ad9f" counter_id="ST/US/SBFMW" env="prod"></span><span item_type="announcement" item_id="516465046129807617" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 8.901 M.</p><p>EPS: As of FY2025 Q1, the actual value is USD -0.44.</p><p></p><h3>Segment Revenue</h3><ul><li>Sales for the three months ended March 31, 2025, were $8,901,341, compared to $7,541,046 for the same period in 2024, representing an increase of $1,360,295 or 18.0%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825003701/sunshine_i10q-033125.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Gross profit for the three months ended March 31, 2025, was $2,730,426, compared to $2,354,337 for the same period in 2024, an increase of $376,089.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825003701/sunshine_i10q-033125.htm"></span></li><li>Loss from operations for the three months ended March 31, 2025, was - $1,295,750, compared to - $1,350,589 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825003701/sunshine_i10q-033125.htm"></span></li><li>Net loss for the three months ended March 31, 2025, was - $1,179,771, compared to - $1,283,801 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825003701/sunshine_i10q-033125.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities was - $1,713,835 during the three months ended March 31, 2025, compared to - $3,185,158 during the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825003701/sunshine_i10q-033125.htm"></span></li><li>Cash flows used in investing activities were - $176,024 for the three months ended March 31, 2025, compared to - $668,736 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825003701/sunshine_i10q-033125.htm"></span></li><li>Cash flows provided by financing activities were $338,137 during the three months ended March 31, 2025, compared to $5,398,149 during the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825003701/sunshine_i10q-033125.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company has 70 generic prescription drugs on the market in Canada and 64 additional drugs in the pipeline, with 13 anticipated launches during the remainder of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825003701/sunshine_i10q-033125.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>The company aims to lower its cost of goods sold from approximately 70% to possibly 60% to reach breakeven and reduce dependency on capital markets for financing.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825003701/sunshine_i10q-033125.htm"></span></li><li>Sunshine Biopharma plans to expand its generic pharmaceuticals operations and continue research and development activities, including potential clinical trials.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825003701/sunshine_i10q-033125.htm"></span></li></ul>

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 8.901 M